02
PCR Impact & Financial Report 2020-21 | pcr.org.uk
Small charity, big ambition. WHO WE ARE
PCR was founded in 1988 as a charity to help scientists receive funding from larger organisations. We may be small but we have come a long way since our beginnings over 30 years ago. Today, we are Prostate Cancer Research and we are funding more leading scientists than ever before, are actively finding gaps in the research system and directing our funding to plug those gaps, and are changing the way scientists and patients connect.
OUR MISSION Together, we will develop and deliver breakthrough medicines and treatments.
This year we have shown resilience in a crisis and have continued to scale up our research capacity to achieve our mission. Our worldclass scientists are dedicated to creating brand new prostate cancer treatments with the potential to reduce the side effects, dramatically cut the cost of treatment and ultimately to change the outcome.
OUR GROWTH TARGETS
2016
2021/22 2023/24
Income
£1.36 million
£2.7 million
>£5.0 million
Projects 4
15
23
Scope
Funding multiple research projects across the UK
World centre of excellence for prostate cancer under ‘virtual centre’ model
Primarily single institute (King’s College London)
Extra activities Open competitive grant call
Funding the gaps in the prostate cancer research ecosystem
Developed our Patient Panel
Patient Voice Hubs across the country
Establish US office Funding for collaboration (projected to represent 10% of expenditure)
First translational research investment
